Archive
532 articles, sorted by publication time.
AI drug discovery no longer attracts capital solely on the strength of platform stories; when a multinational pharmaceutical company writes the right to advance candidate molecules clinically into a contract, Hong Kong’s biotech market also begins facing a stricter question of evidence.
When standard therapies reach the end of the line, clinical trials often sit at the boundary between hope and uncertainty; as a new drug trial begins, the real questions will be safety, eligible patient groups, and early signals of efficacy.
A new round of Hong Kong biotech stories is no longer just about new molecules in the laboratory, but also about how data, algorithms, and clinical risk are being repriced by capital markets.
When standard therapies have been exhausted, clinical trials are often an entry point where hope and uncertainty coexist; as a new anticancer drug enters human research, its true value will depend on safety, depth of response, and subsequent validation.
A phase 1 trial brings non-genetically engineered autologous T cells into the treatment of diffuse pontine glioma and recurrent pediatric central nervous system tumors; the initial responses are notable, but this remains only the starting point on the path to proving efficacy.
A Nature Medicine study proposes a blood circular RNA signature as a tool for early diagnosis and disease-course prediction in Alzheimer’s disease. Its signal is exciting, but before it can truly enter the clinic, it still needs prospective validation and testing in real-world practice settings.
A new Nature Medicine study moves COMPASS from the name of an algorithm toward a research tool that can be inspected, downloaded, and retrained; its value lies not only in predicting who may benefit, but also in forcing the clinical community to redefine how model evidence should be trusted.
This collaboration with Insilico makes Big Pharma’s AI strategy clearer: not treating models as promotional tools, but putting them into the workflow for generating and screening drug candidates. Still, while the market can calculate the deal value first, scientific success or failure will have to wait for experimental data.
As major pharmaceutical companies compete in antibodies, cell therapies, and nucleic acid drugs, Molecure is betting on orally available, finely tunable small molecules; the real dividing line will be whether early clinical signals can support larger development commitments.
The U.S. FDA has allowed Vertex's sickle cell disease gene therapy to be used in children as young as two, signaling that a one-time treatment is entering the disease course earlier; but in pediatric care, the real test lies not only in efficacy, but also in pre-treatment conditioning, long-term follow-up, and family decision-making.
MedCTA tests medical AI agents in tasks that interweave imaging, pathology, and reports; the results show that if a model takes the wrong tool path, even strong answer-generation ability is difficult to translate into a reliable clinical workflow.
Six new medicines were recommended for approval, moving once-weekly basal insulin, an influenza vaccine for older adults, and a rare-disease neurology drug closer to market; but negative opinions for a cell therapy and microbiome products also underscored that innovative platforms cannot bypass the thresholds of clinical credibility and manufacturing quality.